Navigation Links
Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017
Date:8/31/2010

ical Pipeline by Mechanism of Action 44

4.6 Hormone Therapy Pipeline – Pipeline by Phase of Clinical Development 45

4.6.1 Hormone Therapy – Phase III Pipeline 46

4.6.2 Hormone Therapy – Phase II Pipeline 47

4.6.3 Hormone Therapy – Phase I Pipeline 48

4.6.4 Hormone Therapy – Preclinical Pipeline 49

4.6.5 Hormone Therapy – Discovery Pipeline 50

4.7 Discontinued / Suspended Drugs for Hormone Replacement Therapy 50

4.8 Key Takeaway 51

5 Hormone Replacement Therapeutics Market: Implications for Future Market Competition 52

6 Hormone Therapy Market: Future Players in Hormone Therapy Market 54

6.1 Introduction 54

6.2 Pfizer 54

6.2.1 Company Overview 54

6.2.2 Business Description 55

6.2.3 Hormone Therapeutics Portfolio 56

6.3 Merck & Co. 57

6.3.1 Company Overview 57

6.3.2 Business Description 57

6.3.3 Hormone Therapeutics Portfolio 58

6.4 Amgen 58

6.4.1 Company Overview 58

6.4.2 Business Description 59

6.4.3 Hormone Therapeutics Portfolio 60

6.5 BioSante Pharmaceuticals 60

6.5.1 Company Overview 60

6.5.2 Business Description 60

6.5.3 Hormone Therapeutics Portfolio 61

6.6 Noven Pharmaceuticals 61

6.6.1 Company Overview 61

6.6.2 Business Description 61

6.6.3 Hormone Therapeutics Portfolio 62

6.7 Bionovo, Inc. 62

6.7.1 Company Overview 62

6.7.2 Business Description 62

6.7.3 Hormone Therapeutics Portfolio 63

6.8 QuatRx Pharmaceuticals Company 63

6.8.1 Company Overview 63

6.8.2 Hormone Therapeutics Portfolio 64

6.9 Depomed Inc. 64

6.9.1 Company Overview 64

6.9.2 Business Description 64

6.9.3 Hormone Therapeutics Portfolio 65

7 Hormone Therapeutics Market: Appendix 66

7.1 Definitions 66

7.2 Acronyms 66

7.3 Scope of Pipeline
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
2. Reportlinker Adds Threats to Avastin - Targeting the VEGF Pathway
3. Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015
4. Reportlinker Adds Epigenetics: Current and future applications that are driving novel drug discovery
5. Reportlinker Adds Clinical Laboratory Testing Volume 1: Reagents and Instruments
6. Reportlinker Adds Portable and Transport Ventilator Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016
7. Reportlinker Adds Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions
8. Reportlinker Adds Strategic Analysis of End-user Preferences in the U.S. Stem Cell Research Tools Markets
9. Reportlinker Adds Production and Market of Xylose in China
10. Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED
11. Reportlinker Adds European Markets for Small Joint Reconstructive Devices 2010 (15 Countries)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SYDNEY and SOUTHAMPTON , ... -- Australian pharmaceutical company Pharmaxis Ltd (ASX: PXS) and UK biotechnology ... into a research collaboration to develop a selective inhibitor to ... fatal lung disease idiopathic pulmonary fibrosis (IPF). ... US. Current products are expected to produce global revenues in ...
(Date:8/4/2015)... VIEW, Calif. , Aug. 4, 2015  IRIDEX ... James H. Mackaness , who had served as chief ... since 2012, has resigned his positions with the Company, ... officer position at another company. Mr. Mackaness intends to ... Company,s second quarter earnings announcement and 10-Q filing. ...
(Date:8/4/2015)...   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... ended June 30, 2015 and provided a summary ... second quarter of 2015 and recent period marked ... Paul Grint, M.D., President and CEO of Regulus. ...
Breaking Medicine Technology:Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 2Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 3IRIDEX Chief Financial Officer Resigns to Accept Another Opportunity 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 3Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 4Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 5Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 6Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 7Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 8Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 9Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 10
... Reaffirms Primacy and Safety of ,First Generation, Antisense, ... (Nasdaq: GNTA ) announced the presentation of ... lead anticancer,compound, can be safely administered in high ... data were presented by Dr. Anthony Tolcher, Director,of ...
... - Studies Show Improvement in Hemodynamics and Delay ... Actelion Pharmaceuticals US, Inc.,today announced positive results from ... and effective as a combination therapy,for the treatment ... suggest that Tracleer, when given in combination with ...
Cached Medicine Technology:Genasense(R) Can be Administered by Brief High-Dose IV Infusion 2Genasense(R) Can be Administered by Brief High-Dose IV Infusion 3Genasense(R) Can be Administered by Brief High-Dose IV Infusion 4Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 2Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 3
(Date:8/5/2015)... , ... August 05, 2015 , ... ... have just published updated guidelines for the management of malignant pleural mesothelioma. Details ... to read the article. , The updated guidelines issued by the European ...
(Date:8/5/2015)... ... August 05, 2015 , ... Friendly Smiles Dental ... practice; Dr. Daniel H. Huynh, DMD and Dr. Michael J. Foley, DMD. The full ... patients at all three location in the Tampa Bay area, where Friendly Smiles Dental ...
(Date:8/5/2015)... ... ... Social Security benefits are not keeping pace with rising household budgets, according ... Citizens League (TSCL). The record low growth in cost-of-living adjustments (COLAs) in recent ... age 65 and older, says TSCL. , When asked to select between four statements ...
(Date:8/5/2015)... ... , ... Stelari introduces their new collection, The Earth’s Song, inspired by the ... Earth’s Song. Combining fashion and activewear, Stelari’s new collection let’s you take your bohemian ... this collection is sure to make the spirit seeker swoon with prints as meaningful ...
(Date:8/5/2015)... ... ... A leader in Primary Care Continuing Medical Education (CME), Continuing Education ... as its new Director of Program Management. , Su has over 16 years experience ... Primary Care Network (PCN) as the Director, Program Implementation as well as Supervisor of ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Treatment Guidelines Issued By European Researchers, According to Surviving Mesothelioma 2Health News:Friendly Smiles Dental Care Welcomes New Doctors 2Health News:Majority of Older Americans Say Social Security Benefits Not Keeping up with Rising Household Costs, According to a New Survey from the Senior Citizens League 2Health News:Majority of Older Americans Say Social Security Benefits Not Keeping up with Rising Household Costs, According to a New Survey from the Senior Citizens League 3Health News:Stelari: Bohemian Chic Activewear Line 2Health News:Stelari: Bohemian Chic Activewear Line 3Health News:Leading Continuing Medical Education (CME) Provider, Continuing Education Company (CEC), hires expert Su Barnwell as Director of Program Management 2Health News:Leading Continuing Medical Education (CME) Provider, Continuing Education Company (CEC), hires expert Su Barnwell as Director of Program Management 3
... Cancer At All Stages Steps Away From Home, ... ... Medical University of,South Carolina (MUSC) Foundation for Research and Development announced ... for bladder cancer have shown to be accurate for only 40 ...
... of,National Problem Gambling Awareness Week, the state departments ... of counseling,and treatment services available to those affected ... not only the gambler but also their family,and ... Commonwealth,of Pennsylvania is committed to addressing compulsive gambling ...
... 10 Medco Health,Solutions, Inc. (NYSE: MHS ) ... follows:, On Monday, March 17, 2008, Timothy C. ... Inc., Medco,s specialty pharmacy,subsidiary, is scheduled to address the ... at the Boston Marriott Copley,Place will begin at 1:45 ...
... health insurance programs do not provide coverage to international ... ... Seven Corners, one of the,industry,s most experienced travel health insurance ... they,plan to travel abroad for spring break vacations. Most health insurance,programs ...
... be getting them, study says , , MONDAY, March 10 (HealthDay ... choices for kidney cancer more than clinical factors such as ... finds. , This means many patients who are candidates ... where only part of the kidney is removed, may not ...
... ZARS Pharma, Inc. announced,today the completion of ... promotion and distribution rights for all markets ... (lidocaine and tetracaine) Cream,7%/7%, a topical anesthetic ... patients undergoing potentially painful cosmetic and other,skin ...
Cached Medicine News:Health News:Cell Receptor on Track for Painless Bladder Cancer Test 2Health News:State Agencies Highlight Available Assistance During Problem Gambling Awareness Week 2Health News:Medco to Present at Cowen and Company and Lehman Brothers Health Care Conferences 2Health News:Seven Corners Alerts Spring Breakers that They Need Travel Insurance to Vacation Abroad 2Health News:Seven Corners Alerts Spring Breakers that They Need Travel Insurance to Vacation Abroad 3Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 2Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 3Health News:ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic 2Health News:ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Fenestrated large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Fenestrated large type 1/1 (mm), opening width 7.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 7.7 mm....
Medicine Products: